Biotech Values

[DewDiligence]

Re: Zetia / Vytorin

>To be honest, I thought the drop off was going to be sharper than it has been. But maybe I'm being overly harsh since they've lost 33% of their market share in 11 months.<

Most observers expected a significant one-time drop in market share when the poor results in the ENHANCE study came to light. What’s notable is that, almost a year later, the Zetia/Vytorin franchise continues to lose about 30 basis points of market share each month.

Perhaps even more notable is that ex-US sales of Zetia and Vytorin have not been affected by this story. I have a theory about this, but I’d like to hear your take first.